TANGO ASO (Unnamed)
Autosomal Dominant Optic Atrophy (ADOA)
PreclinicalDemonstrated promise for treating underlying cause
Key Facts
Indication
Autosomal Dominant Optic Atrophy (ADOA)
Phase
Preclinical
Status
Demonstrated promise for treating underlying cause
Company
About Stoke Therapeutics
Stoke Therapeutics is developing first-in-class RNA medicines designed to address the underlying genetic causes of severe diseases by restoring protein expression. The company's core TANGO (Targeted Augmentation of Nuclear Gene Output) platform represents a distinct approach in RNA therapeutics, targeting haploinsufficiencies. With its lead program in Phase 3 for Dravet syndrome and promising preclinical data in autosomal dominant optic atrophy (ADOA), Stoke is positioned to potentially deliver disease-modifying therapies. The company is publicly traded and is advancing a pipeline focused on severe genetic disorders of the central nervous system and eye.
View full company profileTherapeutic Areas
Other Autosomal Dominant Optic Atrophy (ADOA) Drugs
| Drug | Company | Phase |
|---|---|---|
| ABO-505 | Abeona Therapeutics | Preclinical |